Exploring the Efficacy of Application Managing Somatic Symptoms Disorder & Medically Unexplained Symptoms (MUS) : A Pilot Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 46
- 试验地点
- 1
- 主要终点
- Somatic Symptom Severity (Patient Health Questionnaire-15; PHQ-15)
研究概览
简要总结
Objectives The primary objective of this study is to evaluate the effectiveness of an eight-week self-management mobile application for adults experiencing somatic symptom disorder (SSD) or medically unexplained symptoms (MUS). Improvement will be assessed using the PHQ-15. The secondary objective is to examine changes in clinical symptoms and physiological indicators following app use, as well as to assess the acceptability and usability of the intervention.
Scientific Rationale Somatic symptoms without clear medical explanation account for 15-30% of primary care visits (Peveler et al., 1997; Fink et al., 1999; Ko et al., 2011). Diagnostic terminology has evolved from somatoform disorders in DSM-IV and MUS to SSD in DSM-5, which emphasizes distressing symptoms accompanied by maladaptive thoughts, emotions, or behaviors (Scott et al., 2022). SSD is frequently associated with alexithymia, emotional suppression, and difficulty regulating anger, consistent with theories of somatization as the bodily expression of unprocessed affect (Anuk & Bahadir, 2017; Liu et al., 2011). These difficulties contribute to interpersonal impairment and excessive health care use, often resulting in frustration for clinicians (Orzechowska et al., 2020).
Psychological treatments, including CBT, MBSR, MBCT, and ACT, have demonstrated efficacy in reducing symptom burden across conditions such as IBS, fibromyalgia, tinnitus, and chronic fatigue (Hauge et al., 2015; Kikuchi et al., 2020; Roland et al., 2015). These therapies share mechanisms such as enhancing mind-body awareness, reducing physiological hyperarousal, and promoting adaptive coping and acceptance (Aktas et al., 2019; Jing et al., 2019). However, barriers to dissemination remain, as patients with SSD often reject psychological explanations, engage in medical shopping, and maintain strong somatic attributions (Brown, 2007; Harris et al., 2009).
Digital interventions offer a scalable solution by providing psychoeducation on mind-body connections, CBT- and mindfulness-based strategies, stress management tools, and behavioral monitoring in an accessible, daily-life format. Evidence suggests that internet- and app-based CBT programs can improve somatic distress and related outcomes, while also reducing treatment costs and improving adherence (Van et al., 2022).
Physiological measures such as heart rate variability (HRV) provide an objective biomarker of stress regulation. Lower HRV reflects reduced resilience and greater emotional dysregulation, while higher HRV indicates excessive arousal or impaired recovery. Despite theoretical links between autonomic regulation and somatization, few studies have examined HRV responses in SSD populations alongside psychological interventions. This study addresses that gap.
Study Design A randomized controlled trial will recruit 110 adults aged ≥19 years who report significant somatic distress. After screening and informed consent, participants will be randomly assigned (1:1) to intervention (n=55) or control (n=55) using an R-generated allocation table managed independently of investigators.
Baseline assessments include standardized questionnaires and HRV measurement. The intervention group will use the mobile application for eight weeks, while the control group will continue treatment as usual. After eight weeks, both groups will complete follow-up questionnaires and HRV measurement. Subsequently, the intervention group will discontinue app use, and the control group will be offered app access. An additional follow-up survey will be conducted online for both groups at 16 weeks.
Expected Impact This study will provide empirical evidence on the efficacy, usability, and acceptability of a digital intervention for SSD and MUS. By integrating self-management strategies with physiological monitoring, it aims to advance scalable, evidence-based approaches for a population that has historically been difficult to treat within traditional medical models.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
盲法说明
Open-label trial; no masking of participants, care providers, investigators, or outcome assessors.
入排标准
- 年龄范围
- 19 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults aged 19 years or older
- •PHQ-15 score of 4 or higher
- •Presence of medically unexplained physical symptoms (MUS)
- •No significant impairment in reading or writing ability
- •Familiarity with smartphone and internet use
排除标准
- •Current diagnosis of substance use disorder (alcohol or drugs)
- •Current diagnosis of schizophrenia or bipolar disorder, or presence of psychiatric symptoms deemed by the clinician to interfere with participation
- •Currently receiving psychotherapy specifically for somatic symptoms
- •Diagnosis of developmental disorders such as autism or intellectual disability, or evidence of significant cognitive impairment
- •Any other medical condition deemed by the clinician to make participation inappropriate
- •Inability to continue participation due to smartphone malfunction or lack of sufficient smartphone skills
研究组 & 干预措施
App Intervention Group
Participants in this group will use the mobile self-management application for somatic symptom disorder and medically unexplained symptoms for 8 weeks, in addition to receiving their usual care.
干预措施: Arm I (App Intervention) (Behavioral)
App Intervention Group
Participants in this group will use the mobile self-management application for somatic symptom disorder and medically unexplained symptoms for 8 weeks, in addition to receiving their usual care.
干预措施: Arm II (Waitlist Control) (Behavioral)
Waitlist Control Group
Participants in this group will continue treatment as usual for 8 weeks without access to the mobile application. After the primary 8-week period, they will be offered access to the application.
结局指标
主要结局
Somatic Symptom Severity (Patient Health Questionnaire-15; PHQ-15)
时间窗: Baseline, 8 weeks after intervention start (V2), 16 weeks after intervention start (V3)
The primary outcome is the change in somatic symptom severity measured by the Patient Health Questionnaire-15 (PHQ-15). The PHQ-15 is a 15-item self-report scale developed to assess the severity of somatic symptoms in primary care (Kroenke et al., 1998) and validated in psychiatric outpatient populations (Han et al., 2009). Scores range from 0 to 30, with higher scores indicating greater somatic symptom burden.
次要结局
- Somatic Symptom Disorder B-Criteria Scale (SSD-12)(Baseline, 8 weeks after intervention start, and 16 weeks after intervention start)
- Patient Health Questionnaire-9 (PHQ-9)(Baseline, 8 weeks after intervention start, and 16 weeks after intervention start)
- Generalized Anxiety Disorder-7 (GAD-7)(Baseline, 8 weeks after intervention start, and 16 weeks after intervention start)
- Liebowitz Social Anxiety Scale, Self-Rated (LSAS-SR)(Baseline, 8 weeks after intervention start, and 16 weeks after intervention start)
- Korean Version of the Five Facet Mindfulness Questionnaire - Short Form (FFMQ-SF)(Baseline, 8 weeks after intervention start, and 16 weeks after intervention start)
- Acceptance and Action Questionnaire-II (AAQ-II)(Baseline, 8 weeks after intervention start, and 16 weeks after intervention start)
- Cognitive Emotion Regulation Questionnaire (CERQ)(Baseline, 8 weeks after intervention start, and 16 weeks after intervention start)
- Intolerance of Uncertainty Scale - Short Form (IUS-12)(Baseline, 8 weeks after intervention start, and 16 weeks after intervention start)
- Forms of Self-Criticism/Attacking and Self-Reassuring Scale (FSCRS)(Baseline, 8 weeks after intervention start, and 16 weeks after intervention start)
- Illness Attitudes Scale (IAS)(Baseline, 8 weeks after intervention start, and 16 weeks after intervention start)
- Korean Multidimensional Assessment of Interoceptive Awareness (K-MAIA)(Baseline, 8 weeks after intervention start, and 16 weeks after intervention start)
- Korean Shapiro Control Inventory (K-SCI; Control and Desire for Control Subscales)(Baseline, 8 weeks after intervention start, and 16 weeks after intervention start)
- App Usability and Acceptability(Baseline, 8 weeks after intervention start, and 16 weeks after intervention start)
研究者
Jooyoung Oh
Clinical Associate Professor
Gangnam Severance Hospital
